An additional 1-year of follow-up confirmed the safety and activity of SHR-A1811 in HER2-expressing or -mutant solid tumors, including breast cancer.
Drs Camidge and Boire discuss Dr Boire’s path to becoming a physician-scientist and how cellular biology research can improve outcomes for patients with cancer.
An abstract is unavailable.
Presented by the AHNS Reconstructive Head & Neck Surgery Section Moderator: Chad Zender, MD, Professor Otolaryngology, Director Head and Neck Surgery, University Of Cincinnati AHNS…
Tanios S. Bekaii-Saab, MD, and Yelena Y. Janjigian, MD, preview top presentations from this year’s Gastrointestinal Cancers Symposium.
During our combined 35 years working to advance diagnostic capabilities for cancer—as a pathologist and as a bioinformatician, respectively—we’ve had the opportunity to help build…
OST-HER2 led to significant 12-month event-free survival and demonstrated favorable overall survival trends at 1 and 2 years in recurrent, fully resected osteosarcoma and lung…
Optimizing Treatment Strategies for Localized and Advanced Genitourinary MalignanciesPresented by Fox Chase Cancer Center and the Temple Health Office for Continuing Medical Education.
PHILADELPHIA (January 21, 2025) — Yash Chhabra, PhD, Assistant Professor in the Cancer Signaling and Microenvironment Research Program at Fox Chase Cancer Center, was recently…
Dr. Aditya Bardia presents real-world findings on elacestrant, demonstrating prolonged real-world progression-free survival (rwPFS) in ER+/HER2- advanced breast cancer patients across all clinically relevant subgroups,…
Standardizing surgical outcomes and better training oncologic surgeons may be accomplished through the use of AI.
